The 2026 DHHS Unified Agenda, published July 3 at reginfo.gov, puts four regulatory actions on a December 2026 or sooner timeline that will directly change how clinical operations and study startup teams work. The most consequential is a final rule requiring single IRB review for all FDA-regulated multisite cooperative research in the United States. Federally funded studies have operated under similar requirements since the revised Common Rule took effect, but this would be the first time the mandate extends to FDA-regulated trials. That gap has let sponsors and CROs run parallel IRB tracks for years; a final rule in December closes it.
The sIRB rule is not the only item with teeth. A separate NPRM targeting 21 CFR 312 Subpart D sponsor and investigator responsibilities is also slated for December. FDA frames the revision as aligning requirements with the modern trial ecosystem, but the actual scope will not be known until the NPRM publishes. For ops teams, the practical risk is that two large regulatory rewrites land simultaneously, requiring process updates before the scope of either is fully settled. A third action, the Phase 1 IND reform rulemaking, carries a July 2026 target date already marked with an asterisk in the Agenda, meaning it may slip. That proposal travels alongside Operation TrialBlazer, an expedited IND pilot launched September 15, 2026, which would pair sponsors with qualified research institutions offering integrated regulatory, IRB, and conduct capabilities, and contemplates rolling IND submissions to shorten the path to first-in-human studies.
Two narrower actions round out the set. OHRP plans to expand exemptions for low-risk research and clarify when protocol changes qualify for expedited review rather than full board consideration, which would redirect startup workflows for studies that currently sit just inside IRB oversight thresholds. FDA also has a final rule pending that would broaden IND exemptions for studies involving lawfully marketed foods, dietary supplements, or cosmetics, an item with limited reach for most sponsors but material for organizations whose pipelines concentrate there.
The Agenda is a statement of intent, not a mandate. None of these entries change current requirements on their own, and several carry dates that have already moved. The December target for the sIRB final rule is the one to hold: if it publishes on schedule, sites and CROs that have not updated their reliance agreements and recordkeeping processes for non-institution IRBs will be caught short at the moment the requirement becomes enforceable.
Source link: https://www.advarra.com/blog/2026-dhhs-unified-agenda-what-clinical-operations-and-study-startup-teams-should-watch/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
